Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Frequently asked questions
What sector does Outlook Therapeutics Inc (OTLK) operate in?
Outlook Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Outlook Therapeutics Inc (OTLK) current stock price?
As of the latest data, Outlook Therapeutics Inc stock price is $0.53, with a previous close of $0.51. Outlook Therapeutics Inc gained $0.01 in the last trading session, representing a 2.34% increase.
What is Outlook Therapeutics Inc (OTLK) current market capitalization?
Outlook Therapeutics Inc market cap is approximately 127.88 million.
What is Outlook Therapeutics Inc (OTLK) Earnings Per Share (EPS)?
The trailing EPS is -$0.70, and the forward EPS is -$0.12.
What is Outlook Therapeutics Inc (OTLK) EBITDA?
Outlook Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -20.28 million.
Does Outlook Therapeutics Inc (OTLK) pay dividends?
No. Outlook Therapeutics Inc does not pay a dividend.
How did Outlook Therapeutics Inc (OTLK) perform in its most recent earnings report?
In the last report (June 30, 2026), Outlook Therapeutics Inc posted an EPS surprise of 0% and a revenue surprise of -99.07%.
What is Outlook Therapeutics Inc (OTLK) beta (volatility) score?
Outlook Therapeutics Inc has a beta of 0.752, indicating lower volatility than the overall market.
